Vascular endothelium as a target of immune response in renal transplant rejection

Frontiers in Immunology

Volumn 5, Issue OCT, 2014, Pages

  Piotti, Giovanni ^a   Palmisano, Alessandra ^a   Maggiore, Umberto ^a   Buzio, Carlo ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Accommodation; Angiotensin II type 1 receptor; Antibody mediated rejection; Endothelial cell antigens; MTOR inhibitors; Regulatory T cells; Renal transplantation; Vimentin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BELATACEPT; BETA4 INTEGRIN; CD45 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; HLA A ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VIMENTIN; VON WILLEBRAND FACTOR;

ANTIGEN ANTIBODY REACTION; AUTOIMMUNITY; BLOOD GROUP ABO SYSTEM; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE REGULATION; CELLULAR IMMUNITY; ENDOTHELIUM CELL; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; PROTEIN EXPRESSION; REVIEW; VASCULAR ENDOTHELIUM;

EID: 84918811457     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00505     Document Type: Review

References (101)

1. Sayegh MH, Carpenter CB. Transplantation 50 years later - progress, challenges, and promises. N Engl J Med (2004) 351:2761-6. doi:10.1056/NEJMon043418
2. U.S. Renal Data System. USRDS 2011 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (2011).
3. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol (2005) 5(10):807-17. doi:10.1038/nri1702
4. Hill GS, Nochy D, Loupy A. Accelerated arteriosclerosis: a form of transplant arteriopathy. Curr Opin Organ Transplant (2010) 15(1):11-5. doi:10.1097/MOT.0b013e3283342684
5. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol (2007) 7(10):803-15. doi:10.1038/nri2171
6. Rose ML. editor. The immune response to endothelial cells. Transplant-Associated Coronary Artery Vasculopathy, Chapter 3. Austin, TX: Landes Bioscience, Georgetown Texas USA; Eurekah.com (2001). p. 71-89.
7. Glotz D, Lucchiari N, Pegaz-Fiornet B, Suberbielle-Boissel C. Endothelial cells as targets of allograft rejection. Transplantation (2006) 82(1 Suppl):S19-21. doi:10.1097/01.tp.0000231348.55262.5a
8. Rose ML. Endothelial cells as antigen-presenting cells: role in human transplant rejection. Cell Mol Life Sci (1998) 54:965-78. doi:10.1007/s000180050226
9. Terasaki PI. Humoral theory of transplantation. Am J Transplant (2003) 3(6):665-73. doi:10.1034/j.1600-6143.2003.00135.x
10. Rydberg L. AB0-incompatibility in solid organ transplantation. Transfus Med (2001) 11:325-42. doi:10.1046/j.1365-3148.2001.00313.x
11. Warner PR, Nester TA. AB0-incompatible solid-organ transplantation. Am J Clin Pathol (2006) 125(Suppl 1):S87-94. doi:10.1309/8W4X9H6F8FTLCGYX
12. Starzl TE, Marchioro TL, Holmes JH, Hermann G, Brittain RS, Stonington H, et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery (1964) 55:195-200.
13. Nelson PW, Landreneau MD, Luger AM, Pierce GE, Ross G, Shield CF III, et al. Ten-year experience in transplantation of A2 kidneys into B and 0 recipients. Transplantation (1998) 65:256-60. doi:10.1097/00007890-199801270-00020
14. Dipchand AI, Pollock BarZiv SM, Manlhiot C, West LJ, VanderVliet M, McCrindle BW. Equivalent outcomes for pediatric heart transplantation recipients: ABO-blood group incompatible versus ABO-compatible. Am J Transplant (2010) 10(2):389-97. doi:10.1111/j.1600-6143.2009.02934.x
15. Slapak M, Naik RB, Lee HA. Renal transplant in a patient with major donor-recipient blood group incompatibility: reversal of acute rejection by the use of modified plasmapheresis. Transplantation (1981) 31:4-7. doi:10.1097/00007890-198101000-00002
16. Flint SM, Walker RG, Hogan C, Haeusler MN, Robertson A, Francis DM, et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant (2011) 11(5):1016-24. doi:10.1111/j.1600-6143.2011.03464.x
17. Montgomery RA, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation (2009) 87(8):1246-55. doi:10.1097/TP.0b013e31819f2024
18. Hung SY, Lin TM, Chang MY, Wang HH, Lee YC, Ho LC, et al. Risk factors of sensitization to human leukocyte antigen in end-stage renal disease patients. Hum Immunol (2014) 75(6):531-5. doi:10.1016/j.humimm.2014.02.024
19. Morris PJ, Mickey MR, Singal DP, Terasaki PI. Serotyping for homotransplantation. XXII, Specificity of cytotoxic antibodies developing after renal transplantation. Br Med J (1969) I:758-9. doi:10.1136/bmj.1.5646.758
20. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med (2011) 365(4):318-26. doi:10.1056/NEJMoa1012376
21. Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis1 B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and non-adherence. Am J Transplant (2012) 12(2):388-99. doi:10.1111/j.1600-6143.2011.03840.x
22. Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation (2002) 74(8):1192-4. doi:10.1097/00007890-200210270-00025
23. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong vanHuyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 369:1215-26. doi:10.1056/NEJMoa1302506
24. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 14(2):272-83. doi:10.1111/ajt.12590
25. Feucht HE, Felber E, Gokel MJ, Hillebrand G, Nattermann U, Brockmeyer C, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol (1991) 86(3):464-70. doi:10.1111/j.1365-2249.1991.tb02954.x
26. Kluth-Pepper B, Schneeberger H, Lederer SR, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int (2001) 59:334-41. doi:10.1046/j.1523-1755.2001.00495.x
27. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet (2005) 365:1570-6. doi:10.1016/S0140-6736(05)66458-6
28. Sumitran-Holgersson S, Wilczek HE, Holgersson J, Söderström K. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation (2002) 74(2):268-77. doi:10.1097/00007890-200207270-00019
29. Mizutani K, Terasaki P, Rosen A, Esquenazi V, Miller J, Shih RN, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant (2005) 5(9):2265-72. doi:10.1111/j.1600-6143.2005.01016.x
30. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant (2007) 7(2):408-15. doi:10.1111/j.1600-6143.2006.01644.x
31. Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 357(13):1293-300. doi:10.1056/NEJMoa067160
32. Cox ST, Stephens HA, Fernando R, Karasu A, Harber M, Howie AJ, et al. Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation. Hum Immunol (2011) 72(10):827-34. doi:10.1016/j.humimm.2011.05.004
33. Narayan S, Tsai EW, Zhang Q, Wallace WD, Reed EF, Ettenger RB. Acute rejection associated with donor-specific anti-MICA antibody in a highly sensitized pediatric renal transplant recipient. Pediatr Transplant (2011) 15(1):E1-7. doi:10.1111/j.1399-3046.2010.01407.x
34. Grafft CA, Cornell LD, Gloor JM, Cosio FG, Gandhi MJ, Dean PG, et al. Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol Dial Transplant (2010) 25(1):307-10. doi:10.1093/ndt/gfp526
35. Sumitran-Karuppan S, Tyden G, Reinholt F, Berg U, Moller E. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol (1997) 5(4):321-7. doi:10.1016/S0966-3274(97)80016-0
36. Perrey C, Brenchley PE, Johnson RW, Martin S. An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol (1998) 6(2):101-6. doi:10.1016/S0966-3274(98)80024-5
37. Shin YS, Yang CW, Ahn HJ, Park CW, Jin DC, Kim YS, et al. Clinical significance of anti-endothelial cell antibody in renal transplant recipients. Korean J Intern Med (2001) 16(1):24-9.
38. Grandtnerová B, Laca L, Jahnová E, Horváthová M, Baláz V, Hovoricová B, et al. Hyperacute rejection of living related kidney graft caused by IgG endothelial specific antibodies with a negative monocyte cross-match. Ann Transplant (2002) 7(4):52-4.
39. Le Bas-Bernardet S, Hourmant M, Coupel S, Bignon JD, Soulillou JP, Charreau B. Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant (2003) 3(2):167-77. doi:10.1034/j.1600-6143.2003.00021.x
40. Sun Q, Liu Z, Yin G, Chen H, Chen J, Li L. Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases. Transplantation (2005) 79(12):1759-62. doi:10.1097/01.TP.0000163290.19788.E7
41. Rodríguez PC, Arroyave IH, Mejía G, García LF. Detection of alloantibodies against non-HLA antigens in kidney transplantation by flow cytometry. Clin Transplant (2000) 14(5):472-8. doi:10.1034/j.1399-0012.2000.140505.x
42. Pontes LF, Carvalho L, Stumbo AC, Porto LC. Detection and localization of non-HLA-ABC antigenic sites relevant to kidney rejection on endothelial cells. J Immunol Methods (2001) 251(1-2):73-80. doi:10.1016/S0022-1759(01)00309-X
43. Breimer ME, Rydberg L, Jackson AM, Lucas DP, Zachary AA, Melancon JK, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation (2009) 87(4):549-56. doi:10.1097/TP.0b013e3181949d4e
44. Alheim M, Johansson SM, Hauzenberger D, Grufman P, Holgersson J. A flow cytometric crossmatch test for simultaneous detection of antibodies against donor lymphocytes and endothelial precursor cells. Tissue Antigens (2010) 75(3):269-77. doi:10.1111/j.1399-0039.2009.01439.x
45. Jackson AM, Lucas DP, Melancon JK, Desai NM. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation (2011) 92(1):54-60. doi:10.1097/TP.0b013e31821b60e9
46. Canet E, Devallière J, Gérard N, Karam G, Giral M, Charreau B, et al. Profiling posttransplant circulating antibodies in kidney transplantation using donor endothelial cells. Transplantation (2012) 93(3):257-64. doi:10.1097/TP.0b013e31823ec0ec
47. Ronda C, Borba SC, Ferreira SC, Glotz D, Ianhez LE, Rodrigues H, et al. Non-human leukocyte antigen antibodies reactive with endothelial cells could be involved in early loss of renal allografts. Transplant Proc (2011) 43(4):1345-8. doi:10.1016/j.transproceed.2011.03.059
48. Sun Q, Liu Z, Chen J, Chen H, Wen J, Cheng D, et al. Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection. Clin J Am Soc Nephrol (2008) 3(5):1479-86. doi:10.2215/CJN.04451007
49. Sigdel TK, Li L, Tran TQ, Khatri P, Naesens M, Sansanwal P, et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol (2012) 23(4):750-63. doi:10.1681/ASN.2011060596
50. Dinavahi R, George A, Tretin A, Akalin E, Ames S, Bromberg JS, et al. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol (2011) 22(6):1168-78. doi:10.1681/ASN.2010111183
51. Hernandez NM, Casselbrant A, Joshi M, Johansson BR, Sumitran-Holgersson S. Antibodies to kidney endothelial cells contribute to a "leaky" glomerular barrier in patients with chronic kidney diseases. Am J Physiol Renal Physiol (2012) 302(7):F884-94. doi:10.1152/ajprenal.00250.2011
52. Li L, Wadia P, Chen R, Kambham N, Naesens M, Sigdel TK, et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Proc Natl Acad Sci U S A (2009) 106(11):4148-53. doi:10.1073/pnas.0900563106
53. Saini D, Weber J, Ramachandran S, Phelan D, Tiriveedhi V, Liu M, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant (2011) 30(6):624-31. doi:10.1016/j.healun.2011.01.708
54. Zhang Q, Reed EF. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol (2010) 22(5):682-8. doi:10.1016/j.coi.2010.08.009
55. Xu Y, Chester AH, Hariri B, McCormack A, Sarathchandra P, Rose ML. The indirect alloimmune response causes microvascular endothelial dysfunction-a possible role for alloantibody. Transplantation (2010) 90(11):1157-64. doi:10.1097/TP.0b013e3181fa9480
56. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 352(6):558-69. doi:10.1056/NEJMoa035717
57. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, et al. Patients with preeclampsia develop agonistic antibodies against the angiotensin AT1 receptor. J Clin Invest (1999) 103:945-52. doi:10.1172/JCI4106
58. Reinsmoen NL, Lai CH, Heidecke H, Haas M, Cao K, Ong G, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation (2010) 90(12):1473-7. doi:10.1097/TP.0b013e3181fd97f1
59. Rose ML. Role of anti-vimentin antibodies in allograft rejection. Human Immunol (2013) 74:1459-62. doi:10.1016/j.humimm.2013.06.006
60. Barber LD, Whitelegg A, Madrigal JA, Banner NR, Rose ML. Detection of vimentin-specific autoreactive CD8+ T cells in cardiac transplant patients. Transplantation (2004) 77(10):1604-9. doi:10.1097/01.TP.0000129068.03900.25
61. Carter V, Shenton BK, Jaques B, Turner D, Talbot D, Gupta A, et al. Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc (2005) 37(2):654-7. doi:10.1016/j.transproceed.2004.12.043
62. Leong HS, Mahesh BM, Day JR, Smith JD, McCormack AD, Ghimire G, et al. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor. J Leukoc Biol (2008) 83(2):263-71. doi:10.1189/jlb.0607339
63. Mahesh B, Leong HS, Nair KS, McCormack A, Sarathchandra P, Rose ML. Autoimmunity to vimentin potentiates graft vasculopathy in murine cardiac allografts. Transplantation (2010) 90(1):4-13. doi:10.1097/TP.0b013e3181dfa694
64. Snanoudj R, Candon S, Legendre C. Targeting B cells in sensitized kidney transplant patients: state of the art and future perspectives. Curr Opin Organ Transplant (2010) 15(6):709-15. doi:10.1097/MOT.0b013e3283402cf4
65. Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant (2009) 9:2459-65. doi:10.1111/j.1600-6143.2009.02819.x
66. Tobian AA, Shirey RS, Montgomery RA, Cai W, Haas M, Ness PM, et al. AB0 anitbody titer and risk of antibody-mediated rejection in AB0-incompatible renal transplantation. Am J Transplant (2010) 10:1247-53. doi:10.1111/j.1600-6143.2010.03103.x
67. KissmeyerNielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with preexisting humoral antibodies against donor cells. Lancet (1966) 2(7465):6625.
68. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, Cameron SJ, Bao C, Fox-Talbot K, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A (2007) 104(4):1301-6. doi:10.1073/pnas.0602035104
69. Fuggle SV, Sanderson JB, Gray DW, Richardson A, Morris PJ. Variation in expression of endothelial adhesion molecules in pre transplant and transplanted kidneys correlation with intra graft events. Transplantation (1993) 55(1):11723.
70. Cavender DE, Haskard DO, Joseph B, Ziff M. Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayer. J Immunol (1986) 136(1):203-7.
71. Cavender DE, Saegusa Y, Ziff M. Stimulation of endothelial cell binding of human lymphocytes by tumor necrosis factor. J Immunol (1987) 139(6):1855-60.
72. Yu CL, Haskard D, Cavender DE, Johnson AR, Ziff M. Human gamma interferon increases the binding of T lymphocytes to endothelial cell monolayer. Clin Exp Immunol (1985) 62(1):554-60.
73. Harris PE, Bian H, Reed EF. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immun (1997) 159:5697-704.
74. Ziegler ME, Souda P, Jin Y, Whitelegge JP, Reed EF. Characterization of the endothelial cell cytoskeleton following HLA class I ligation. PLoS One (2012) 7(1):e29472. doi:10.1371/journal.pone.0029472
75. Zhang X, Rozengurt E, Reed EF. HLA class I molecules partner with Integrin ß4 to stimulate endothelial cell proliferation and migration. Sci Signal (2014) 3(149):1-25. doi:10.1126/scisignal.2001158
76. Jindra PT, Jin Y, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol (2008) 180:2357-66. doi:10.4049/jimmunol.180.4.2357
77. Chopek MW, Simmons RL, Platt JL. ABO-incompatible kidney transplantation: initial immunopathologic evaluation. Transplant Proc (1987) 19(6):4553-7.
78. Rose ML, West LJ. Accommodation: does it apply to human leukocyte antigens? Transplantation (2012) 93(3):244-6. doi:10.1097/TP.0b013e31823f468c
79. Salama AD, Delikouras A, Pusey CD, Cook HT, Bhangal G, Lechler RI, et al. Transplant accommodation in highly sensitized patients: a potential role for Bc - xL and allo.antibody. Am J Transplant (2001) 1:260-9. doi:10.1034/j.1600-6143.2001.001003260.x
80. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol (2004) 34:2303-12. doi:10.1002/eji.200324843
81. Jindra PT, Zhang X, Mulder A, Claas F, Veale J, Jin YP, et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation (2006) 82:S33-5. doi:10.1097/01.tp.0000231447.34240.3c
82. Jindra PT, Hsueh A, Hong L, Gjertson D, Shen XD, Gao F, et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol (2008) 180(4):2214-24. doi:10.4049/jimmunol.180.4.2214
83. Pober JS, Orosz CG, Rose ML, Savage CO. Can graft endothelial cells initiate a host anti-graft immune response? Transplantation (1996) 61(3):343-9. doi:10.1097/00007890-199602150-00001
84. Epperson DE, Pober JS. Antigen-presenting function of human endothelial cells. Direct activation of resting CD8 T cells. J Immunol (1994) 153(12):5402-12.
85. Kreisel D, Krupnick AS, Balsara KR, Riha M, Gelman AE, Popma SH, et al. Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol (2002) 169:6154-61. doi:10.4049/jimmunol.169.11.6154
86. Kreisel D, Krupnick AS, Gelman AE, Engels FH, Popma SH, Krasinskas AM, et al. Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med (2002) 8(3):233-9. doi:10.1038/nm0302-233
87. Savage C, Hughes CC, Pepinsky RB, Wallner BP, Freedman AS, Pober JS. Endothelial cell lymphocyte function-associated antigen-3 and an unidentified ligand act in concert to provide costimulation to human peripheral blood CD4+ T cells. Cell Immunol (1991) 137(1):15063. doi:10.1016/0008-8749(91)90065-J
88. Adams PW, Lee HS, Waldman WJ, Sedmak DD, Morgan CJ, Ward JS, et al. Alloantigenicity of human endothelial cells. 1. Frequency and phenotype of human T helper lymphocytes that can react to allogeneic endothelial cells. J Immunol (1992) 148(12):375360.
89. Page C, Thompson C, Yacoub M, Rose M. Human endothelial stimulation of allogeneic T cells via a CTLA4 independent pathway. Transpl Immunol (1994) 2(4):3427. doi:10.1016/0966-3274(94)90013-2
90. Murakami K, Ma W, Fuleihan R, Pober JS. Human endothelial cells augment early CD40 ligand expression in activated CD41 T Cells through LFA-3-mediated stabilization of mRNA. J Immunol (1999) 163:2667-73.
91. Marelli-Berg FM, Frasca L, Weng L, Lombardi G, Lechler RI. Antigen recognition influences transendothelial migration of CD4+ T Cells. J Immunol (1999) 162:696-703.
92. Zelenika D, Adams E, Mellor A, Simpson E, Chandler P, Stockinger B, et al. Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol (1998) 161(4):1868-74.
93. Taflin C, Favier B, Baudhuin J, Savenay A, Hemon P, Bensussan A, et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A (2011) 108(7):2891-6. doi:10.1073/pnas.1011811108
94. Agorogiannis EI, Regateiro FS, Howie D, Waldmann H, Cobbold SP. Th17 cells induce a distinct graft rejection response that does not require IL-17A. Am J Transplant (2012) 12(4):835-45. doi:10.1111/j.1600-6143.2011.03971.x
95. Kendal AR, Chen Y, Regateiro FS, Ma J, Adams E, Cobbold SP, et al. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med (2011) 208(10):2043-53. doi:10.1084/jem.20110767
96. Thebault P, Condamine T, Heslan M, Hill M, Bernard I, Saoudi A, et al. Role of IFNc in allograft tolerance mediated by CD4+CD25+ regulatory T cells by induction of IDO in endothelial cells. Am J Transplant (2007) 7:2472-82. doi:10.1111/j.1600-6143.2007.01960.x
97. Wang C, Yi T, Qin L, Maldonado RA, von Andrian UH, Kulkarni S, et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J Clin Invest (2013) 123(4):1677-93. doi:10.1172/JCI66204
98. Krupnick AS, Gelman AE, Barchet W, Richardson S, Kreisel FH, Turka LA, et al. Cutting edge: murine vascular endothelium activates and induces the generation of allogeneic CD4 25 Foxp3 regulatory T Cells. J Immunol (2005) 175:6265-70. doi:10.4049/jimmunol.175.10.6265
99. Wang C, Qin L, Manes TD, Kirkiles-Smith NC, Tellides G, Pober JS. Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2. J Exp Med (2014) 211(3):395-404. doi:10.1084/jem.20131125
100. Maganto-García E, Bu DX, Tarrio ML, Alcaide P, Newton G, Griffin GK, et al. Foxp3+-inducible regulatory T cells suppress endothelial activation and leukocyte recruitment. J Immunol (2011) 187:3521-9. doi:10.4049/jimmunol.1003947
101. Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the benefit study. Am J Transplant (2013) 13(11):2875-83. doi:10.1111/ajt.12460